Chemex announces results of pilot study with masoprocol cream for reversal of symptoms of photoaged skin.
Sixty-four patients participated in a double-blinded study in which four groups of patients with mild to moderate photodamaged skin applied vehicle, 0.25%, 1.0% or 2.5% masoprocol cream once-a-day for up to twelve weeks. The results indicate that all three groups treated with masoprocol cream demonstrated improvement in overall severity of their photodamaged skin, while patients treated with vehicle did not show any improvement. These initial results indicate that masoprocol, in low concentrations, when applied topically, can improve the appearance of photodamaged skin. Photodamaged skin is a result of excessive sun exposure which damages skin cells resulting in pre-mature aging of the skin.
The number and severity of dermal adverse reactions observed in the study were less frequent and milder than expected. However, the dermal side effect profile experienced by some patients was judged to be unacceptable for long term use for the treatment of photoaged skin. Accordingly, a new stable formulation of masoprocol creams has been developed, which will be tested to determine if this new formulation will reduce the dermal side effects to an acceptable level. Additional human studies using the new formulations are planned to commence during the first quarter of 1995.
Chemex is a leader in developing new prescription drugs for the treatment of various skin diseases.
CONTACT: Chemex Pharmaceuticals Inc., Fort Lee
Len Stigliano, 201/944-1449
|Printer friendly Cite/link Email Feedback|
|Date:||Nov 1, 1994|
|Previous Article:||GeneMedicine names Tanina Frouge as Vice President, Financing & Investor Relations.|
|Next Article:||PRESSLINK EXPLORER(TM) BRINGS THE WORLD'S DIGITAL CONTENT DIRECT TO THE DESKTOP; PressLink, Knight-Ridder's Founder of Online News Delivery, Says...|